Private equity firm focused on lower-middle-market healthcare services and life sciences companies, typically deploying growth and buyout capital to regional operators and specialty services. The firm targets revenue and EBITDA-accretive platforms that benefit from consolidation, regulatory complexity, and recurring payor relationships. Investment approach emphasizes operational partnership, roll-up strategies, and clinical management support to drive margin expansion and scale prior to exit to strategic buyers or larger PE sponsors.
Private equity firm focused on lower-middle-market healthcare services and life sciences companies, typically deploying growth and buyout capital to regional operators and specialty services. The firm targets revenue and EBITDA-accretive platforms that benefit from consolidation, regulatory complexity, and recurring payor relationships. Investment approach emphasizes operational partnership, roll-up strategies, and clinical management support to drive margin expansion and scale prior to exit to strategic buyers or larger PE sponsors.
Targets lower‑middle‑market healthcare services and life sciences businesses, deploying growth and buyout capital to regional operators and specialty services. Prioritizes platform investments that can scale through roll‑ups, clinical operations optimization, and payer relationship stabilization. Underwriting emphasizes recurring revenue, regulatory defensibility, and EBITDA-accretive add‑ons. Capital deployment combines operational partnership and board-level clinical governance to expand margins and exit to strategic buyers or larger sponsors.
Targets lower‑middle‑market healthcare services and life sciences businesses, deploying growth and buyout capital to regional operators and specialty services. Prioritizes platform investments that can scale through roll‑ups, clinical operations optimization, and payer relationship stabilization. Underwriting emphasizes recurring revenue, regulatory defensibility, and EBITDA-accretive add‑ons. Capital deployment combines operational partnership and board-level clinical governance to expand margins and exit to strategic buyers or larger sponsors.
| Trades 963 | Longs Won 671/963 69% | Profit Factor 3.39 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $296,304.37 |
| Average Win $51,857.04 | Best Trade (Jul 13) $5.49M | Sharpe Ratio -13.9 |
| Average Loss -$35,190.64 | Worst Trade (Dec 31) -$6.6M | Z-Score 11.95 (100%) |
| Commissions $0 | Avg. Trade Length 9m 1w 1d | Expectancy $25,462.52 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 6,849 | 6,164 | 5,479 | 4,795 | 4,110 | 3,425 | 2,740 | 2,055 | 1,370 | 685 |